Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU6OFP)

• Drug Name: Dyclonine Drug Info
• Synonyms: Diclonia; Diclonina; Dyclocaine; Dyclocainum; Dyclonin; Dycloninum; Dyclothane; Tanaclone; Diclonina [INN-Spanish]; Dyclonine (INN); Dyclonine [INN:BAN]; Dycloninum [INN-Latin]; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-(9CI); 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 3-Piperidino-4'-butoxypropiophenone; 4'-Butoxy-3-piperidinopropiophenone; 4-butoxy-beta-piperidinopropiophenone; 4-n-butoxy-beta-(1-piperidyl)propiophenone

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1]
Pruritus	EC90	Investigative	[2]

• Therapeutic Class: Anesthetics
• Cross-matching ID:
  PubChem CID: 3180
  ChEBI ID: CHEBI:4724
  CAS Number: CAS 586-60-7
  TTD Drug ID: DMU6OFP

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[6]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[7]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[6]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[7]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[8]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[9]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[10]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[11]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[3]
Hexylcaine	DMEADRK	Anaesthesia	9A78.6	Approved	[11]

Drug(s) Affected By Acetylcholinesterase (ACHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[12]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[13]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[14]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[15]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[16]
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[14]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[17]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[18]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[19]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[20]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[21]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[22]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[23]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[24]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[24]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[25]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[26]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[27]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[28]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Blocker	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[4]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7173).
• [2] Dyclonine FDA Label
• [3] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [4] Profiling the Tox21 Chemical Collection for Acetylcholinesterase Inhibition. Environ Health Perspect. 2021 Apr;129(4):47008. doi: 10.1289/EHP6993. Epub 2021 Apr 12.
• [5] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [6] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [7] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [8] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [9] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [10] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [12] Monitoring the reaction of carbachol with acetylcholinesterase by thioflavin T fluorescence and acetylthiocholine hydrolysis. Chem Biol Interact. 2008 Sep 25;175(1-3):235-41. doi: 10.1016/j.cbi.2008.06.002. Epub 2008 Jun 17.
• [13] Effect of reversible ligands on oxime-induced reactivation of sarin- and cyclosarin-inhibited human acetylcholinesterase. Toxicol Lett. 2015 Feb 3;232(3):557-65.
• [14] Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
• [15] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [16] Tribromophenol induces the differentiation of SH-SY5Y human neuroblastoma cells in vitro. Toxicol In Vitro. 2003 Oct-Dec;17(5-6):635-41. doi: 10.1016/s0887-2333(03)00110-3.
• [17] Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol. 1989 Nov 28;173(1):53-64. doi: 10.1016/0014-2999(89)90008-3.
• [18] Interaction of dichlorvos and anticholinesterases on the in vitro inhibition of human blood cholinesterases. Toxicol Appl Pharmacol. 1974 Feb;27(2):456-63.
• [19] Hairy-root organ cultures for the production of human acetylcholinesterase. BMC Biotechnol. 2008 Dec 23;8:95.
• [20] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [21] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [22] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [23] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [24] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [25] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [26] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [27] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [28] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.